JP2010525025A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525025A5
JP2010525025A5 JP2010504692A JP2010504692A JP2010525025A5 JP 2010525025 A5 JP2010525025 A5 JP 2010525025A5 JP 2010504692 A JP2010504692 A JP 2010504692A JP 2010504692 A JP2010504692 A JP 2010504692A JP 2010525025 A5 JP2010525025 A5 JP 2010525025A5
Authority
JP
Japan
Prior art keywords
phenyl
compound
pyrimidin
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504692A
Other languages
English (en)
Japanese (ja)
Other versions
JP5566880B2 (ja
JP2010525025A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2008/055017 external-priority patent/WO2008129080A1/en
Publication of JP2010525025A publication Critical patent/JP2010525025A/ja
Publication of JP2010525025A5 publication Critical patent/JP2010525025A5/ja
Application granted granted Critical
Publication of JP5566880B2 publication Critical patent/JP5566880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504692A 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体 Expired - Fee Related JP5566880B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2007/003608 2007-04-24
EP2007003608 2007-04-24
EP07106951 2007-04-25
EP07106951.2 2007-04-25
PCT/EP2008/055017 WO2008129080A1 (en) 2007-04-24 2008-04-24 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases

Publications (3)

Publication Number Publication Date
JP2010525025A JP2010525025A (ja) 2010-07-22
JP2010525025A5 true JP2010525025A5 (enExample) 2011-06-23
JP5566880B2 JP5566880B2 (ja) 2014-08-06

Family

ID=39745232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504692A Expired - Fee Related JP5566880B2 (ja) 2007-04-24 2008-04-24 プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体

Country Status (4)

Country Link
US (2) US8507498B2 (enExample)
EP (1) EP2137166B1 (enExample)
JP (1) JP5566880B2 (enExample)
WO (1) WO2008129080A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047266A1 (en) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
EA026917B1 (ru) * 2010-03-22 2017-05-31 Лид Дискавери Сентр Гмбх Фармацевтически активные производные двузамещенного триазина
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
CN103562184B (zh) * 2011-03-02 2016-04-27 利德探索中心有限公司 药学活性的二取代的吡啶衍生物
KR20140019381A (ko) 2011-04-19 2014-02-14 바이엘 인텔렉쳐 프로퍼티 게엠베하 치환된 4-아릴-n-페닐-1,3,5-트리아진-2-아민
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
US9108926B2 (en) * 2011-09-16 2015-08-18 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
WO2013037894A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
HRP20180285T1 (hr) * 2012-08-23 2018-04-20 Virostatics Srl Novi 4,6-disupstituirani derivati aminopirimidina
CA2888383A1 (en) * 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group
JP2015536311A (ja) 2012-10-18 2015-12-21 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含有する4−(オルト)−フルオロフェニル−5−フルオロピリミジン−2−イルアミン
CN104854091B (zh) 2012-10-18 2018-04-03 拜耳药业股份公司 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
CN104918918B (zh) * 2012-11-15 2017-10-24 拜耳药业股份公司 含磺亚胺基团的4‑(邻)‑氟苯基‑5‑氟嘧啶‑2‑基胺
TW201418243A (zh) * 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
JP6263193B2 (ja) 2012-11-15 2018-01-17 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン基を含んでいる5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体
JP6371385B2 (ja) 2013-07-04 2018-08-08 バイエル ファーマ アクチエンゲゼルシャフト スルホキシイミン置換5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体およびそのcdk9キナーゼ阻害薬としての使用
EP3650023A1 (en) * 2013-10-04 2020-05-13 Aptose Biosciences Inc. Compositions for treating cancers
AR098394A1 (es) 2013-11-25 2016-05-26 Lilly Co Eli Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
JP2017508757A (ja) 2014-03-13 2017-03-30 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含有する5−フルオロ−n−(ピリジン−2−イル)ピリジン−2−アミン誘導体
EP3126338B1 (en) 2014-04-01 2019-09-04 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
EP3126525B1 (en) 2014-04-04 2020-02-19 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
EP3129387B1 (en) 2014-04-11 2019-06-26 Bayer Pharma Aktiengesellschaft Novel macrocyclic compounds
WO2016061144A1 (en) 2014-10-14 2016-04-21 The Regents Of The University Of California Use of cdk9 and brd4 inhibitors to inhibit inflammation
CN107207475A (zh) 2014-10-16 2017-09-26 拜耳医药股份有限公司 含有砜基团的氟化苯并呋喃基‑嘧啶衍生物
WO2016059086A1 (en) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
JP2018509439A (ja) 2015-03-24 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト 多発性骨髄腫を治療するための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
JP2018509440A (ja) 2015-03-24 2018-04-05 バイエル ファーマ アクチエンゲゼルシャフト リンパ腫の治療のための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用
HUE043440T2 (hu) 2015-06-29 2019-08-28 Astrazeneca Ab Policiklusos amidszármazékok mint CDK9 inhibitorok
ES2786552T3 (es) 2015-09-29 2020-10-13 Bayer Pharma AG Compuestos de sulfondiimina macrocíclicos nuevos
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2018017426A1 (en) 2016-07-16 2018-01-25 Florida State University Research Foundation, Inc. Compounds and methods for treatment and prevention of flavivirus infection
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
US11254690B2 (en) 2017-03-28 2022-02-22 Bayer Pharma Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
US10555942B2 (en) 2017-10-10 2020-02-11 Florida State University Research Foundation, Inc. Emetine compounds for treatment and prevention of flavivirus infection
CN111417395A (zh) 2017-10-30 2020-07-14 艾普托斯生物科学公司 用于治疗癌症的芳基咪唑
KR102764122B1 (ko) 2018-02-13 2025-02-05 바이엘 악티엔게젤샤프트 미만성 거대 b-세포 림프종을 치료하기 위한 5-플루오로-4-(4-플루오로-2-메톡시페닐)-n-[4-[(s-메틸술폰이미도일)메틸]피리딘-2-일]피리딘-2-아민의 용도
WO2020235672A1 (ja) * 2019-05-23 2020-11-26 国立大学法人京都大学 アルツハイマー病のための医薬組成物
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9319568D0 (en) 1993-09-22 1993-11-10 Euro Celtique Sa Pharmaceutical compositions and usages
GB2361236B (en) 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
US6949544B2 (en) 2001-03-29 2005-09-27 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20040106647A1 (en) 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
US7576085B2 (en) 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7419984B2 (en) * 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
WO2004041164A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
AU2004259346A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
EP1709007A1 (en) 2004-01-22 2006-10-11 Altana Pharma AG N-4-(6-(heteo)aryl-pyrimidin-4-ylaminophenyl)-benzenesulfonamides as kinase inhibitors
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
US20090221581A1 (en) * 2005-05-25 2009-09-03 Philipp Wabnitz Methods of treating pain
US8507511B2 (en) * 2007-04-24 2013-08-13 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
JP5693951B2 (ja) * 2007-04-24 2015-04-01 アストラゼネカ エービー プロテインキナーゼの阻害剤
US8389521B2 (en) * 2007-04-24 2013-03-05 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases

Similar Documents

Publication Publication Date Title
JP2010525025A5 (enExample)
JP2004536814A5 (enExample)
RU2412937C2 (ru) Соединения трехзамещенного амина и их применение в качестве ингибиторов белка переноса холестерилового эфира (сетр)
JP2013523710A5 (enExample)
HRP20241159T1 (hr) Heterociklički agonisti za glp-1
JP2020023577A5 (enExample)
JP2010512337A5 (enExample)
KR20090128478A (ko) 페닐 아미노 피리미딘 화합물 및 이의 용도
RU2016115803A (ru) Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
RU2006146985A (ru) Модуляторы мускариновых рецепторов
JP2009541268A5 (enExample)
SI2797918T1 (en) Bromodomain inhibitors
JP2020529405A5 (enExample)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2011519854A5 (enExample)
RU2507205C2 (ru) Арилциклогексилэфиры дигидротетраазабензоазуленов для применения в качестве антагонистов рецептора вазопрессина v1a
RU2017104918A (ru) СОЛЬ ПРИСОЕДИНЕНИЯ КИСЛОТЫ СОЕДИНЕНИЯ, ИНГИБИРУЮЩЕГО Trk
JP2016512844A5 (enExample)
JP2017515836A5 (enExample)
ME02763B (me) Derivati bipirazola kao inhibitori jak
RU2009133846A (ru) Новые производные гидантоина в качестве ингибиторов металлопротеиназ
JP2013510876A5 (enExample)
JP2010513272A5 (enExample)
JP2015503529A5 (enExample)
AU2023204378A1 (en) Pyridinamine-Pyridone And Pyrimidinamine-Pyridone Compounds